Dr. Ryan Vandry, a member of CPDD, has released new, science-driven recommendations to help guide federal policy on hemp-derived cannabinoid products, emphasizing a balanced approach that protects public health while preserving access to beneficial therapies.
Developed in concert with leading scientists in the field of cannabis research and pharmacology, the recommendations address growing concerns around unregulated, high-dose intoxicating cannabinoid products while recognizing the important role that non-intoxicating, full-spectrum hemp products can play for patients with serious medical conditions. These include individuals managing epilepsy, cancer-related symptoms, and treatment-resistant mental health disorders.
Central to the recommendations is the establishment of evidence-based dose limits for delta-9-THC across different product types. Vandry suggests a maximum of 2.5 mg of THC per serving for orally ingested products, citing clinical research showing no meaningful impairment at or below this level. For inhalable products, stricter controls are advised, including a 1 mg per dose limit and requirements for metered delivery systems. In contrast, topical products are not recommended to have THC limits due to negligible absorption and lack of abuse potential.
The guidance also calls for broader regulatory safeguards, including age restrictions, standardized testing and labeling, and maintaining appropriate CBD-to-THC ratios to reduce risk.
Importantly, Vandry warns that overly restrictive policies could unintentionally eliminate full-spectrum hemp products from the legal market, potentially driving patients toward unregulated sources and increasing public health risks.
CPDD thanks members Dr. Vandry, Ziva D Cooper, PhD, Margaret Haney, PhD, and Elise Weerts, PhD for their work on these recommendations.
Dr. Vandrey has given permission for the letter to be shared with legislative offices seeking education on dosing limits for Cannabis.